September 2024


SkIN Canada Skin Investigation Network of Canada

E-Bullettin

Funded by

Institute of Musculoskeletal Health and Arthritis

SkIN Canada News

Team Development Awards

1. Objective

This funding opportunity aims to support preliminary activities for developing novel teams and the infrastructure necessary to conduct future multicentre research for the benefit of patients living with skin conditions.

2. Description

The Skin Investigation Network of Canada (SkIN Canada) is offering a funding opportunity to facilitate collaborative research that benefits people living with skin conditions. Funded by the Canadian Institutes of Health Research (CIHR) – Institute of Musculoskeletal Health and Arthritis, SkIN Canada has three main goals: a) develop national infrastructure to advance multicentre skin research; b) foster new collaborations between patients, researchers, and clinicians at academic and community sites; and c) grow the skin research community. We recognize the value of open science and patient engagement to achieve these goals, and have ensured that the patient voice is integrated throughout all our activities.

In accordance with the network’s mission, SkIN Canada will be funding a series of awards to catalyze novel multicentre skin research. These grants are intended to support preliminary activities that are typically not fundable as stand-alone projects. For example, operating grants usually require preliminary work and validated infrastructure to demonstrate feasibility and potential for success.

Deadline: October 15, 2024

LEARN MORE

SkIN Canada Member Awarded CIHR Project Grant

Congratulations to Brett Thombs (PhD) on receiving a 2024 CIHR Project Grant!

Title: Enhancing Patient Engagement in Scleroderma Research: A Series of Cohort-Based Randomized Controlled Trials of Tools to Improve Communication of Research Results.

Lay Abstract:
What will the research be about?
Sharing research results with patients is required by ethical regulations. Yet, most researchers do not share results from their studies with patients. Evidence on what kinds of research communication tools work best for different people is limited. Few studies have compared how effectively different tools (e.g., plain-language summaries, infographics, comics, podcasts) communicate research results to patients. We plan to conduct a series of trials in a large international cohort of people with scleroderma, a rare, autoimmune disease, to address this knowledge gap.

What will be our outcomes?
Study participants will rate communication tools for (1) information completeness; (2) understandability; and (3) ease of use of format. We will also seek suggestions from participants on how to improve tools.

Who will be in the study? People with scleroderma, confirmed by a physician, aged 18 years or older, will be recruited from an ongoing international cohort, the Scleroderma Patient centered Intervention Network Cohort.

What will the research team do? We will conduct a series of 8 trials. In each trial, participants will be randomly assigned to receive different communication tools that share results from a recently published scleroderma research study. Each trial will build upon what is learnt from previous trials. We will conduct analyses among specific groups to assess effectiveness according to patient characteristics (e.g., age, race or ethnicity, country, education).

How will people use the results?
Our results will inform other researchers who will be able to conduct similar studies in other populations. Our results will also be used by researchers and patient organizations who
disseminate research results so that they can tailor the way they disseminate results to patient needs. Patients will be the end users of the knowledge we produce if we can improve how we communicate results to patients.

Complete Summary of Research Proposal:
Background: Research ethics guidance mandates that study results be shared with participants, and CIHR’s Knowledge Translation Strategy emphasizes dissemination to others with relevant lived experiences. Yet, most researchers do not share results with patients, and we do not know which dissemination tools (e.g., lay summaries, infographics, podcasts) or tool features best facilitate effective communication. Only 3 randomized controlled trials (RCTs) have compared tool effectiveness, and none assessed which tools work best for which patients. Comparative effectiveness trials are needed to build an evidence base to help us understand what tools are most effective for communicating different types of research to different patients. We will use the multinational Scleroderma Patient-centered Intervention Network (SPIN) Cohort to conduct a series of RCTs to compare tools among people with systemic sclerosis (SSc), or scleroderma.
Objectives: An effective tool must communicate information patients want to know, understandably, in an easy-to-use format. Our trials will evaluate which dissemination tools most effectively do this and if different tools and tool features are more effective for different types of studies and patients with different sociodemographic or educational characteristics. Primary Objectives: In each trial, we will compare tools based on (1) information completeness; (2) understandability; and (3) ease of use, as prioritized by our Patient Advisory Team. Secondary Objectives: We will evaluate comprehension of key aspects of disseminated research; likelihood that participants would enroll in a similar future study; and, for all primary and secondary outcomes, analyze effects by participant characteristics (e.g., age, country, language, education level, eHealth literacy). Methods: We will conduct a series of 8 pragmatic, parallel-group RCTs that will each compare 2 or more tools or tool variations to a plain-language summary comparator; the common comparator will facilitate across-RCT comparisons. In each trial, SPIN patients and researchers will select SSc research to disseminate. A committee (5 patients, 4 researchers) will select tools to test. Tools will be developed by experienced tool developers, patients, and researchers. SPIN Cohort participants (N = 1,250 and growing) will be randomized to a dissemination tool and complete study outcomes. Analyses will be intent-to-treat and use proportional odds regression models. Feasibility: We have an experienced international team with joint researcher-patient leadership; experts in patient education, knowledge mobilization, SSc, and trial methods; researcher disseminators; and patient organization partners. We have a successful record of conducting RCTs in the SPIN Cohort. Cohort participants are already enrolled and have consented to be included in trials, so no additional recruitment is needed. Knowledge Mobilization: SPIN is a true patient-researcher partnership. Patients are involved in SPIN leadership and project-specific Patient Advisory Teams. A diverse Patient Advisory Team participated in developing this proposal and will contribute to study conduct and dissemination of results. Results will support improved research communication in SSc and similar diseases, directly, and will inform other populations indirectly. Our research will also support other researchers to conduct similar trials in other populations and further contribute to an evidence base.

Featured Profiles – Team Development Award Recipients

Dr. Philippe Lefrancois (2023 Recipient)

Dr. Philippe Lefrancois is an Assistant Professor in the Department of Medicine, Division of Experimental Medicine, at McGill University. His laboratory focuses on enhancing understanding of skin cancers, particularly Basal Cell Carcinoma (BCC), which is the most prevalent of all human cancers. The aim is to enable patients to benefit from new targeted therapies and management options. The research involves defining the cellular and molecular phenotypes of aggressive BCC tumors. Computational biology, genomics, and molecular biology approaches are employed using various sample types, including data from cancer consortia, patient-derived tumors, publicly-available sequencing data from other patient cohorts, and primary cancer cell lines. The emphasis is on identifying novel signaling pathways and actionable targets for BCC, as well as characterizing the BCC tumor microenvironment with a focus on clinically-relevant features.

Team Development Award Project Title: Establishing and optimizing skin cancer biobanking across Québec.

Lay abstract: Non-Melanoma Skin Cancers include the 2 most common human cancers, Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), respsectively. The risk of developing skin cancer in fair skin individuals approach 40%. While most BCC and SCC remain localized and can be cured, 1-4% of them can become more aggressive locally and even spread to other organs. We do not know much about these advanced, more aggressive cancers. The progression from high-risk early BCC/SCC to advanced BCC/SSC is not well understood. High-risk early tumors and advanced tumors are rarely collected and studied, hence targeted treatments are few. In this proposal, we aim to establish and optimize sample collection for skin cancers from patients across several hospitals in Québec, with help from basic science collaborators for determining optimal conditions for liveability and with help from epidemiologists and patient partners to identify important clinical information and make it standard across hospitals. We want to involve patient organizations into improving how clinicians and those involved in biobanking can deliver skin cancer diagnosis and sun awareness messages. Researchers and clinicians will have more data and potential markers of disease severity and aggressivity, and will understand more the development and progression of BCC and SCC.

Scientific Abstract: Keratinocyte carcinomas include the two most common human cancers in Canada, Basal Cell Carcinoma (BCC) and cutaneous Squamous Cell Carcinoma (SCC). Most BCC/SCC can be treated easily but some are locally aggressive or even metastatic, termed advanced BCC/SCC. Events leading to advanced BCC/SCC are unknown. In particular, it is unclear how high-risk early BCC/SCC tumors progress to advanced disease. Despite their common occurrence, these cancers are poorly studied. Biobanking of advanced BCC/SCC tumors is rare, with only 11 advanced BCC tumors and 40 advanced SCC tumors with genomic data available. We have set up a Réseau Recherche Cancer Québec biobank at the Jewish General Hospital / Lady Davis Institute, which is supported as well by the Marathon of Hope – Québec Cancer Consortium. In this proposal, we want to establish similar efforts at other tertiary hospitals in Québec (CHU de Québec). Aim 1) Arrange legal issues related to biobanking province-wide under the Réseau Recherche Cancer Québec and MOH-QCC, Aim 2) Optimize conditions for transport: 1 – from clinic to the lab, and 2 – from one lab to the biobank, Aim 3) Harmonize epidemiology data and clinical data collection across all sites for meaningful biobanking, and include information useful for skin cancer patients, and Aim 4) Determine how delivery of skin cancer diagnosis and sun awareness messages can tailored to the need of skin cancer patients. We hope to provide BCC/SCC researchers with the starting material to understand advanced disease, high-risk early disease, and the establishment of BCC/SCC carcinogenesis, so novel therapeutics and biomarkers can be designed.

Dr. Caitlin Champion (2023 Recipient)

Dr Cait Champion (MD MSc FRCSC) is a rural general surgeon based in Parry Sound ON with the Northern Ontario School of Medicine (NOSM) University.  As an early career researcher she initially connected with Dr Alex Poole and Josianne Gauthier to start the Canadian Frostbite Collaborative research project, identifying the need for broad collaboration and knowledge sharing to improve access to evidence-based frostbite care for patients and providers.  The team has grown to include Dr Sarvesh Logsetty and numerous medical student and resident researchers, patients and community partners.  Her passion for networked care and rural care access has fuelled the growth of this initial project into the establishment of the Canadian Frostbite Care Network launching in October 2024.

Team Development Award Project Title: Canadian Frostbite Collaborative National Website Development

Lay Abstract: Frostbite injury presents significant functional impacts for affected individuals with the possibility of amputation along with increased risk of future cold injury, chronic pain and wound healing challenges in severe cases.  The risk of frostbite increases during unseasonably cold weather, and early medical treatment with potential to significantly improve outcomes can be initiated in most acute medical settings.  Our research has identified the need for easily accessible evidence-based information on modern frostbite care treatments, with the greatest potential impacts among community hospitals, who see the bulk of frostbite presentations, and among marginalized and vulnerable populations, including homeless individuals.  We are working to establish a Canadian Frostbite Care Network, starting with website launch in October 2024, to provide an information and collaboration hub for members of the public and health care professionals enabling timely access to high-quality frostbite care.

Scientific Summary: Frostbite injury presents significant functional impacts including the possibility of amputation along with increased risk of future cold injury, chronic pain and wound healing challenges in severe cases.  Early recognition of injury and initiation of medical treatments with the potential to significantly improve outcomes, such as iloprost and tPA, can be initiated in most acute medical settings.  Standardized care protocols with the potential to improve patient outcomes in frostbite patients are often lacking in community hospitals where the bulk of patients present.  The SkIN team development grant has enabled collaboration between patients and health care providers with frostbite expertise to establish a Canadian Frostbite Care Network website, launching October 2024, to provide evidence-based frostbite care information for members of the public and health care professionals.  Building from scoping reviews of the current evidence in pre-hospital, hospital-based and post-injury care, and providing a centralized hub for up-to-date guidelines and protocols, the network website aims to provide evidence-based information and access to frostbite expertise to enable timely access to high-quality frostbite care.  Working with our patient collaborators and community partners we are developing educational resources for knowledge translation to ensure information is available and accessible for vulnerable populations with the greatest potential benefit for prevention and early treatment of severe injury.  The network website will also serve as a foundation and catalyst for future national and international collaborative research including prospective clinical trials.

Can SkIN Canada help?

Request support for your study

 

SkIN Canada has launched a formal study intake process for investigators requesting support from the Network. Please visit our  RESOURCES page for more information on how we can help with funding, patient engagement, database creation, project administration, ethics application, or statistical support.

Submit Intake Form 

From the Training Committee Hub

Skin Canada Travel and Mobility Awards – Application Deadline October 15, 2024

1. Travel Award: The deadline for the next SkIN Canada Trainee Travel Award is Tuesday October 15 (2024) before 11:59 PM ETSkIN Canada provides partial funding for trainees to attend conferences as part of their training experience. A limited number of awards are available each year on a competitive basis. There are two competition periods per year, one in May and one in October. Applicants who have previously received funding through this program in a fiscal year are not eligible to receive funding until the following fiscal year. The value of the SkIN Canada Travel Award is a maximum of $1,000 CAD. 

 LEARN MORE

 

2. Mobility Award: The deadline for the next SkIN Canada Trainee Mobility Award is Tuesday October 15 (2024) before 11:59 PM ETThe SkIN Canada Trainee Mobility Award provides funding for trainees in the field of skin research to study and conduct research for a brief period in a laboratory other than their own within Canada or abroad as part of their training experience. A limited number of awards are available each year on a competitive basis.  There will be two competition periods per year, one in May and one in October. Applicants are eligible for the award only once during a particular training period or level of study (e.g. MSc, PhD, Clinical residency, or Postdoctoral training).
        The value of the Skin Canada Trainee Mobility Award is up to $4,000 which can be used for the trainee’s research in a laboratory other than their own, within Canada or abroad for a period ranging from 2 weeks to 6 months. 

LEARN MORE

Skin Canada Training Committee Opening

The Training Committee represents skin research trainees from across Canada. The Committee considers representations from across Canada to be valuable. The committee currently has an opening for a PhD student or a post-doctoral fellow from any of the Western Provinces. If interested in joining this dynamic committee, please send your expression of interest and CV  to info@skincanada.org.

SkIN Canada Trainee Webinar – October 10th

 

REGISTER HERE

News from Other Organizations

Scientific Director of the Canadian Institutes of Health Research – Institute of Musculoskeletal Health and Arthritis

The Canadian Institutes of Health Research (CIHR) is seeking a Scientific Director for the Institute of Musculoskeletal Health and Arthritis (CIHR-IMHA), one of CIHR’s 13 health research Institutes.

Scientific Directors (SDs) of CIHR Institutes are leaders in their respective fields who champion and support health research, knowledge mobilization, and capacity development at the highest level of scientific excellence. As key representatives of CIHR, they provide scientific leadership and advice, shaping CIHR’s health research priorities and investment strategies with the goal of improving the health of people in Canada and around the world. This role provides an unparalleled opportunity to mentor and train the next generation of health researchers, advocate for researchers, people with lived experience and other partner communities and give back to the health research ecosystem.

Learn More

Scientific Director of the Canadian Institutes of Health Research – Institute of Musculoskeletal Health and Arthritis

The Network for Canadian Oral Health Research (NCOHR) is seeking Expressions of Interest from individuals interested in serving as Chair or co-Chair of our Indigenous Peoples’ Health working group.  Dr. Trish Goulet has resigned as chair for personal reasons. 

NCOHR offers resources to encourage oral health researchers across Canada to collaborate and communicate with one another, and with our clinical colleagues. We envision that innovative and collaborative oral health research partnerships will make a difference in the health of Canadians.

The mandate of all working groups of NCOHR are to:

  • Support the strategic goals and priorities of the Network. 

  • Share information with its members and their respective oral health 
researchers. 

  • Be involved in periodic presentations, seminars and other events 
that demonstrate excellence in mentorship and education in the field of oral 
health research. 

  • Provide guidance and advice on emerging issues for key stakeholders/funding 
partners (including CIHR-IMHA) 


The role/responsibilities of the Chair are:

  • To provide key leadership within the network and organize the activities of a working group.
  • To organize/lead virtual meetings of working group members.
  • To interface with other working groups and participate in meetings with other chairs.
  • To create awareness of the working group within the oral health research community.

The WG meets virtually a minimum of three times a year. 

Working group members will not be compensated; however, travel and accommodation expenses will be reimbursed in accordance with CIHR travel policy reimbursement guidelines. Additionally, NCOHR will fund events that promote knowledge mobilization, such as webinars, workshops, forums, student exchanges, and open access publications, up to $5,000 annually.

Candidates are required to demonstrate their understanding of the importance of Indigenous-led oral health research and ability to work collaboratively in and with the working group. Applicants are asked to submit an Expression of Interest letter (that includes a statement of the applicant’s relevant experience, expertise, and previous participation in NCOHR activities, vision for the working group and potential strategies to enable moving towards that vision), and a recent Curriculum Vitae.  Priority will be given to applicants who have lived experience of Indigenous (First Nations, Metis, and Inuit) cultures, values and worldviews.
 
Applications are to be sent to ncohr@dal.ca by Friday October 4, 2024.  Applications will be reviewed as received. 

Recent Publications on Skin Research
Inflammatory Skin Conditions 

1. Arora P, Brumley C, Arrington K, Hylwa S. Allergic Contact Dermatitis in Skin of Color: A Retrospective Study from a Comprehensive Patch Testing Center. Dermatitis. Sep 23 2024.https://www.ncbi.nlm.nih.gov/pubmed/39308405
2. Kearns-Turcotte S, McCuaig C, Powell J, Piram M, Marcoux D, Hatami A, Coulombe J. Pediatric BASCULE syndrome in 42 patients: a peek into dysautonomia. J Am Acad Dermatol. Sep 21 2024.https://www.ncbi.nlm.nih.gov/pubmed/39313031
3. Caucheteux SM, Piguet V. Hidradenitis Suppurativa Tunnels Invasive Transcriptional Signature. The Journal of investigative dermatology. Sep 24 2024.https://www.ncbi.nlm.nih.gov/pubmed/39320303
4. Savinova I, Gooderham M, O’Toole A, Cy A, Bawazir M, Abu-Hilal M. Clinical Characteristics and Treatment Patterns of Pityriasis Rubra Pilaris: A Canadian Retrospective Study. J Cutan Med Surg. Sep 25 2024:12034754241287553.https://www.ncbi.nlm.nih.gov/pubmed/39323064
5. Chu AWL, Rayner DG, Chu X, Chen L, Dong AYH, Waserman S, Baker DR, Sheikh J, Moellman J, Lang DM, Ben-Shoshan M, Mathur SK, Beck LA, Khan DA, Oliver ET, Asiniwasis RN, Chan J, Cole EF, Trayes KP, Frazier WT, Runyon L, Wheeler KE, Eftekhari S, Gardner DD, Winders T, Bernstein JA, Saini SS, Chu DK. Topical corticosteroids for hives and itch (urticaria): Systematic review and Bayesian meta-analysis of randomized trials. Ann Allergy Asthma Immunol. Oct 2024;133(4):437-444 e418.https://www.ncbi.nlm.nih.gov/pubmed/38901542

READ MORE

 

Wound Healing, Fibrosis and Regeneration

1.    Safoine M, Paquette C, Gingras GM, Fradette J. Improving Cutaneous Wound Healing in Diabetic Mice Using Naturally Derived Tissue-Engineered Biological Dressings Produced under Serum-Free Conditions. Stem Cells Int. 2024;2024:3601101.https://www.ncbi.nlm.nih.gov/pubmed/38737365
2.    Rijal H, Bouadi N, Piguet V, Mukovozov I. Treatment Outcomes of Scleroderma With Janus Kinase Inhibitors: A Systematic Review. J Cutan Med Surg. Jun 10 2024:12034754241260021.https://www.ncbi.nlm.nih.gov/pubmed/38859662
3.    Arif S, Richer M, Larochelle S, Moulin VJ. Microvesicles derived from dermal myofibroblasts modify the integrity of the blood and lymphatic barriers using distinct endocytosis pathways. J Extracell Biol. May 2024;3(5):e151.https://www.ncbi.nlm.nih.gov/pubmed/38939570
4.    Arif S, Larochelle S, Trudel B, Gounou C, Bordeleau F, Brisson AR, Moulin VJ. The diffusion of normal skin wound myofibroblast-derived microvesicles differs according to matrix composition. J Extracell Biol. Jan 2024;3(1):e131.https://www.ncbi.nlm.nih.gov/pubmed/38938680
5.    Yang Y, Gomez N, Infarinato N, Adam RC, Sribour M, Baek I, Laurin M, Fuchs E. The pioneer factor SOX9 competes for epigenetic factors to switch stem cell fates. Nature cell biology. Jul 24 2023.https://www.ncbi.nlm.nih.gov/pubmed/37488435.

READ MORE

 Skin Cancer

 1. Zvulunov A, Neale H, Stern J, Santaguida P, Stein AB, Koh M, Eichenfield LF, Guitart J, Goebeler M, Scarisbrick J, Willemze R, Coughlin CC, George R, Brazzelli V, Marschalko M, Belousova I, Querfeld C, Bagot M, Szepietowski JC, Papadavid E, Quaglino P, Hoeger P, Ortiz-Romero PL, Nikolaou V, Dummer R, Aung PP, Lawley L, Morel KD, Ngan B, Wain M, Gameiro A, Lacy-Niebla RM, Pope E. Approach to Mycosis Fungoides in children (ARMFUL study): consensus-based recommendations. J Am Acad Dermatol. Aug 22 2024.https://www.ncbi.nlm.nih.gov/pubmed/39181404
2. Weir VR, Dempsey K, Gichoya JW, Rotemberg V, Wong AI. A survey of skin tone assessment in prospective research. NPJ Digit Med. Jul 17 2024;7(1):191.https://www.ncbi.nlm.nih.gov/pubmed/39014060
3. Negbenebor NA. Championing Diversity in Mohs and Cutaneous Oncology: Reducing Disparities in Skin Cancer Care for Patients of Color. Am Soc Clin Oncol Educ Book. Jun 1 2024;44(3):e433376.https://www.ncbi.nlm.nih.gov/pubmed/39013125
4. Narod SA, Metcalfe K, Finch A, Chan AW, Armel SR, Aeilts A, Eisen A, Karlan B, Bordeleau L, Tung N, Foulkes WD, Neuhausen SL, Eng C, Olopade O, Zakalik D, Couch F, Cullinane C, Pal T, Sun P, Kotsopoulos J, Hereditary Breast Cancer Clinical Research G. The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations. Hered Cancer Clin Pract. May 13 2024;22(1):7.https://www.ncbi.nlm.nih.gov/pubmed/38741145
5. Ituarte BE, Taylor MA, Thomas SI, Ehsan E, Griffin J, Fernandez JM, Wei EX. Analysis of increasing prevalence of skin of colour publications in the PubMed database. J Eur Acad Dermatol Venereol. May 11 2024.https://www.ncbi.nlm.nih.gov/pubmed/38733280
  

READ MORE

Skin of Colour

1.    Yasnova N, Sirait SP, Rahmayunita G. The effectiveness and safety of 3% tranexamic acid cream vs. 4% hydroquinone cream for mixed-type melasma in skin of color: a double-blind, split-face, randomized controlled trial. Acta Dermatovenerol Alp Pannonica Adriat. Jun 2024;33(2):83-88.https://www.ncbi.nlm.nih.gov/pubmed/38918942
2.    Yang LJ, Kundu RV. Differences in attitudes toward aging skin between skin of color and non-skin of color consumers: A cross-sectional survey study. JAAD Int. Sep 2024;16:201-203.https://www.ncbi.nlm.nih.gov/pubmed/39040840
3.    Xue GR, Hamzavi IH, Kohli I, Mohammad TF. Challenges of tinted sunscreen in skin of color. Int J Dermatol. Sep 2024;63(9):e221-e222.https://www.ncbi.nlm.nih.gov/pubmed/39215428
4.    Woolery-Lloyd HC. INDIVIDUAL ARTICLE: Skincare in Skin of Color: A Comprehensive Approach to Preprocedure, Intraprocedure, and Postprocedure. J Drugs Dermatol. Aug 1 2024;23(8):62041s62045-62041s62010.https://www.ncbi.nlm.nih.gov/pubmed/39093664
5.    Williams K, Yaldo M, Olds H, Moossavi M. A large exophytic plaque on the shoulder of a skin of color patient. Int J Dermatol. Apr 4 2024.https://www.ncbi.nlm.nih.gov/pubmed/38572509

READ MORE Other

1. Savard E, Magne B, Simard-Bisson C, Martel C, Larouche D, Gauvin R, Moulin VJ, Germain L. Design of an innovative method for measuring the contractile behaviour of engineered tissues. Tissue engineering. Part C, Methods. Sep 23 2024.https://www.ncbi.nlm.nih.gov/pubmed/39311467
2. Richardson KC, Jung K, Matsubara JA, Choy JC, Granville DJ. Granzyme B in aging and age-related pathologies. Trends in molecular medicine. Aug 23 2024.https://www.ncbi.nlm.nih.gov/pubmed/39181801
3. Rayner DG, Liu M, Chu AWL, Chu X, Guyatt GH, Oykhman P, Cao DJ, Moellman J, Ben-Shoshan M, Baker DR, Waserman S, Lang D, Sheikh J, Mathur SK, Beck LA, Khan DA, Oliver ET, Asiniwasis RN, Cole EF, Wheeler KE, Runyon L, Chan J, Trayes KP, Eftekhari S, Gardner DD, Winders T, Saini SS, Bernstein J, Chu DK. Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: a systematic review and meta-analysis of randomized clinical trials. The Journal of allergy and clinical immunology. Jun 7 2024.https://www.ncbi.nlm.nih.gov/pubmed/38852861
4. McDermid A, Lam K, Ko YCK, Schmitt T, Khosravi-Hafshejani T, Dutz JP. Cyclosporin als Erstlinienbehandlung bei SARS‐CoV‐2‐reaktiver infektiöser mukokutaner Eruption bei Erwachsenen. J Dtsch Dermatol Ges. Jul 2024;22(7):1013-1015.https://www.ncbi.nlm.nih.gov/pubmed/38978425
5. McDermid A, Lam K, Ko YCK, Schmitt T, Khosravi-Hafshejani T, Dutz JP. SARS-CoV-2 reactive infectious mucocutaneous eruptions in adults treated with cyclosporine as first line treatment. J Dtsch Dermatol Ges. Jun 4 2024.https://www.ncbi.nlm.nih.gov/pubmed/38837589

READ MORE

SkIN Canada Executive Committee

Contact us


Visit website